Literature DB >> 1736616

Effect of epinephrine on the efficacy of the internal cardioverter-defibrillator.

J Sousa1, W Kou, H Calkins, S Rosenheck, A Kadish, F Morady.   

Abstract

To evaluate the effect of sympathetic activation on the efficacy of the implantable cardioverter-defibrillator (ICD) in converting ventricular tachycardia (VT) or ventricular fibrillation (VF), 32 patients who received an ICD because of life-threatening VT/VF underwent 1 week postimplant ICD testing both before and after infusion of 25 (16 patients) or 50 (16 patients) ng/kg/min of epinephrine for greater than or equal to 12 minutes. These infusion rates are known to result in plasma epinephrine concentrations comparable to mild-moderate stress. The patients' mean age was 63 +/- 10 years; 26 had coronary artery disease, 2 had dilated cardiomyopathy and 4 had no evidence of structural heart disease. VT and VF were induced in 16 patients each by programmed stimulation or alternating current. Among the 16 patients with VT, the first ICD discharge (26 to 30 J) was effective in 15 patients in the baseline state and in all 16 patients during epinephrine infusion. Among patients with VF, the first ICD discharge (26 to 30 J) terminated VF in all patients in the baseline state, compared with 12 of 16 patients during epinephrine infusion (p less than 0.05). In 4 patients, VF was terminated during epinephrine infusion only by the second or third ICD discharge (30 J). In conclusion, physiologic increases in the plasma epinephrine concentration may increase the number and energy of shocks needed to terminate VF.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1736616     DOI: 10.1016/0002-9149(92)90995-b

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

Review 1.  Chronotherapeutics for cardiovascular disease.

Authors:  Y A Anwar; W B White
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

2.  Physical activity recommendations for patients with electrophysiologic and structural congenital heart disease: a survey of Canadian health care providers.

Authors:  Thomas M Roston; Astrid M De Souza; George G S Sandor; Shubhayan Sanatani; James E Potts
Journal:  Pediatr Cardiol       Date:  2013-02-23       Impact factor: 1.655

Review 3.  Inherited primary arrhythmia disorders: cardiac channelopathies and sports activity.

Authors:  S Marrakchi; I Kammoun; E Bennour; L Laroussi; M Ben Miled; S Kachboura
Journal:  Herz       Date:  2018-05-09       Impact factor: 1.443

Review 4.  Athletes with Implantable Cardioverter Defibrillators.

Authors:  Shiva P Ponamgi; Christopher V DeSimone; Michael J Ackerman
Journal:  Clin Sports Med       Date:  2015-07       Impact factor: 2.182

Review 5.  Implantable cardioverter-defibrillators and the young athlete: can the two coexist?

Authors:  Ian H Law; Kevin Shannon
Journal:  Pediatr Cardiol       Date:  2012-03       Impact factor: 1.655

Review 6.  Sport Participation in Patients with Implantable Cardioverter-Defibrillators.

Authors:  Rachel Lampert
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-11-14

7.  Sports participation in patients with implantable cardioverter-defibrillators.

Authors:  R Lampert; B Olshansky
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2012-06

8.  The circadian variation of atrial defibrillation thresholds.

Authors:  Andrew Robert John Mitchell; Eduardo Warman; Katie Schaaf; Neil Sulke
Journal:  J Interv Card Electrophysiol       Date:  2004-02       Impact factor: 1.900

9.  Higher defibrillation threshold in methamphetamine cardiomyopathy patients with implantable cardioverter-defibrillator.

Authors:  Rakesh Malhotra; Shyam Patel; Tekchand Ramchand; Omar Al Nimri
Journal:  Indian Pacing Electrophysiol J       Date:  2017-07-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.